pSivida Corp Announces an Evaluation Agreement with Hospital for Special Surgery To Investigate Bioerodible Sustained Release Systems in Orthopedic Surgery
WATERTOWN, Mass. & NEW YORK--(BUSINESS WIRE)--Drug delivery company pSivida Corp. (NASDAQ: PSDV) (ASX: PVA) today announced it has entered into an evaluation agreement with Hospital for Special Surgery (HSS), a world leader in orthopedics, rheumatology and rehabilitation, to investigate pSivida’s drug delivery technologies in orthopedics.